Savara, Inc. (SVRA)
5.28
+0.24
(+4.76%)
USD |
NASDAQ |
Mar 25, 16:00
5.29
+0.01
(+0.19%)
After-Hours: 20:00
Savara Cash from Investing (Quarterly) : -93.56M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Spyre Therapeutics, Inc. | -247.41M |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
| Alnylam Pharmaceuticals, Inc. | -37.17M |
| BioMarin Pharmaceutical, Inc. | -42.45M |
| Imunon, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -25.06M |
| Cash from Financing (Quarterly) | 135.56M |
| Free Cash Flow | -101.06M |
| Free Cash Flow Per Share (Quarterly) | -0.1043 |
| Free Cash Flow to Equity (Quarterly) | -25.14M |
| Free Cash Flow to Firm (Quarterly) | -25.06M |
| Free Cash Flow Yield | -8.61% |